AIDX — 20/20 Biolabs, Inc.

Nasdaq · Unknown · Unknown · CIK 1139685 ·
Last close
$0.52
Market Cap
$6.62M
52W High
$1.09
52W Low
$0.40
ADV30
114,048
Next earnings
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 353,375 62,884 -1,443,356 -2,174,836 5,803,347 4,219,099 3,046,222
Dec 2025 538,274 130,417 -912,846 -1,307,771 4,137,357 1,025,987 4,156,582
Sep 2025 3,239,449 1,144,855 3,130,993
Mar 2025 553,820 165,795 -772,180 -764,577

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-2,825,371
Investing CF
$-5,354
Financing CF
$5,252,589
CapEx
$-5,354
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.35
As of
2026-08-16

Balance + Analyst (yfinance extras)

Retained Earnings
$-35,422,055
Inventory
$104,523
Receivables
$201,481
ST Investments
EBIT TTM
$-5,103,499
Pretax Income TTM
$-5,496,232
Interest Exp TTM
$392,733
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,040,199
EBITDA
$-4,321,660
Free Cash Flow
$-805,684
Enterprise Value
$4,643,495
Total Cash
$4,546,140
Total Debt
$572,448
Shares Out
12,770,303
Trailing EPS
$-0.58
Book Value
$-0.01
ROE
-331.2%
ROA
-62.4%
Div Yield

Annual Trend (SEC EDGAR, last 3y)

Revenues vs Net Income (last 3y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 2,045,133 -3,330,871 -3,738,821 4,137,357 4,156,582 -1,919,720
Dec 2024 1,752,343 -5,661,057 -5,551,667 3,584,408 2,078,926 -2,598,785
Dec 2023 1,424,304 -6,361,462 -6,391,309 6,367,828 2,080,336 -4,479,971

Peers — same industry

TickerNameMarket CapLastDaily %
KLYG Kelyniam Global, Inc. $6.58M $0.13
LOBO LOBO TECHNOLOGIES LTD. $6.57M $0.65
EDHL Everbright Digital Holding Ltd. $6.67M $4.00
FRFAF Fresh Factory B.C. Ltd. $6.69M $0.66
POM POMDOCTOR Ltd $6.54M $0.97

News headlines (Yahoo Finance, 1h cache)

20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management’s Recent East Asia Business Development Tour
2026-07-30 12:31 · Yahoo
20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy
2026-07-27 20:30 · Yahoo
20/20 BioLabs Announces Monthly Investor Webinar Series to be Held on the First Wednesday of Each Month
2026-06-22 20:45 · Yahoo
20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters
2026-05-27 12:31 · Yahoo
20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress
2026-05-20 20:05 · Yahoo
20/20 BioLabs to Attend Sidoti Micro-Cap Virtual Conference on May 20, 2026
2026-05-14 12:31 · Yahoo
20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress
2026-03-31 20:57 · Yahoo
20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock
2026-07-23 12:31 · Yahoo
20/20 BioLabs Highlights Investor Webinar Focused on OneTest™ for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue Growth
2026-07-09 20:01 · Yahoo
20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level
2026-08-17 12:31 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.